Hanmi Science Co., Ltd.

Equities

A008930

KR7008930000

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
33,550 KRW -1.03% Intraday chart for Hanmi Science Co., Ltd. +0.15% -14.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hanmi Science Co., Ltd. cancelled the transaction announced on January 12, 2024 CI
OCI Holdings Company Ltd. cancelled the acquisition of 10.94% stake in Hanmi Science Co., Ltd. from Song Young Sook, Kim Won Se and Kim JI Woo. CI
Hanmi Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Hanmi Science Co., Ltd.'s Equity Buyback Plan announced on October 24, 2023. CI
Tranche Update on Hanmi Science Co., Ltd.'s Equity Buyback Plan announced on October 24, 2023. CI
Hanmi Science Co., Ltd.'s Equity Buyback announced on October 24, 2023, has expired with 268,859 shares, representing 0.4% for KRW 9,341.62 million. CI
OCI Holdings Company Ltd. signed an agreement to acquire 10.94% stake in Hanmi Science Co., Ltd. from Song Young Sook, Kim Won Se and Kim JI Woo. CI
Hanmi Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hanmi Science's Net Income Doubles in Q3 MT
Hanmi Science Co., Ltd. announces an Equity Buyback for 330,000 shares. CI
Hanmi Science Co., Ltd. authorizes a Buyback Plan. CI
Hanmi Science Co., Ltd. Announces Successful Launch of JVM's Automated Drug Dispensing System via High-End Robot Arm 'MENITH' in the European Market CI
Hanmi Science's Net Income Jumps 70.2% in Q2 MT
Hanmi Science Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hanmi Science's Net Income Jumps 60% in Q1; Shares Decline 3% MT
South Korean Stocks Decline on Uncertainty over US Fed Rate Hike; NCSoft Loses 6% MT
Hanmi Science's Net Income Jumps 107% in Q4 MT
Hanmi Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Hanmi Science's Net Profit Falls 4.8% in Q3 MT
Hanmi Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Hanmi Science's Net Income Jumps 36% in Q2; Shares Rise 3% MT
Hanmi Science Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hanmi Science's Net Income Jumps 45% in Q1 MT
Hanmi Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hanmi Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Chart Hanmi Science Co., Ltd.
More charts
Hanmi Science Co Ltd is a Korean-based holding company principally involved in the management of subsidiaries. Through subsidiaries in Japan, Europe and Korea, the Company operates in three segments. The Pharmaceutical Products Wholesale segment mainly engages in the distribution of pharmaceutical products. The Holding Business segment mainly engages in the business of controlling subsidiaries. The Other segment mainly engage in the production and sales of pharmaceuticals, and the supply of quasi-drugs and health functional foods, beverages and functional cosmetics.
More about the company
  1. Stock Market
  2. Equities
  3. A008930 Stock
  4. News Hanmi Science Co., Ltd.
  5. Hanmi Science's Net Income Jumps 60% in Q1; Shares Decline 3%